يعرض 1 - 10 نتائج من 26 نتيجة بحث عن '"Sabeen Mekan"', وقت الاستعلام: 1.82s تنقيح النتائج
  1. 1
    Abstract CT067: Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study

    المؤلفون: Mor Moskovitz, Isamu Okamoto, Peng Chen, Jilpa Patel, Sabeen Mekan, M. Catherine Pietanza, Yalin Zhu, Renata Eiras, Marcello Tiseo

    المصدر: Cancer Research. 83:CT067-CT067

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1ee8f437f3c19f1d5fbb3cdea5226eb0Test
    https://doi.org/10.1158/1538-7445.am2023-ct067Test


    أضف إلى المفضلة
  2. 2
    Abstract 4396: TROP2 expression in non-small cell lung cancer

    المؤلفون: Peiwen Kuo, Emon Elboudwarej, Lauri Diehl, Jilpa Patel, Sabeen Mekan, Juliane M. Jürgensmeier

    المصدر: Cancer Research. 83:4396-4396

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4cdb6a379fbb73475f7e86155bb0b7acTest
    https://doi.org/10.1158/1538-7445.am2023-4396Test


    أضف إلى المفضلة
  3. 3
    Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

    المؤلفون: Kan Yonemori, Tiffany A. Traina, Yasuaki Sagara, Takahiro Nakayama, Masato Takahashi, Kenichi Inoue, O. P. Sharma, Shigehira Saji, Zhenhao Qi, Akihiko Osaki, Yang Qiu, Sabeen Mekan, Tatsuya Toyama, Hiroshi Onuma, Joyce O'Shaughnessy, Norikazu Masuda, Yutaka Yamamoto, Shunji Takahashi, Ian E. Krop, Hiroji Iwata, Shoichi Ohwada

    المصدر: Cancer Research. 81:PD1-09

    مصطلحات موضوعية: Cancer Research, Antibody-drug conjugate, Oncology, business.industry, Cancer research, Human epidermal growth factor receptor, Medicine, In patient, business, medicine.disease, Metastatic breast cancer

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::423780071f18a81c5a760da7a5a6bfacTest
    https://doi.org/10.1158/1538-7445.sabcs20-pd1-09Test


    أضف إلى المفضلة
  4. 4
    P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer

    المؤلفون: Marwan Fakih, Hiroya Taniguchi, Sabine Tejpar, M. Kanai, J. Beck, Katrina S. Pedersen, G. Pudussery, Yali Liu, Zev A. Wainberg, Kanwal Pratap Singh Raghav, Hisato Kawakami, Arndt Vogel, Kensei Yamaguchi, Sabeen Mekan, Takayuki Yoshino, Scott Kopetz, K. Bando, Yang Qiu

    المصدر: Annals of Oncology. 32:S111

    مصطلحات موضوعية: Oncology, Patritumab, medicine.medical_specialty, business.industry, Colorectal cancer, Phases of clinical research, Hematology, medicine.disease, Internal medicine, medicine, In patient, Open label, Previously treated, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::12ec3039a6026b43fc594982d695d700Test
    https://doi.org/10.1016/j.annonc.2021.05.100Test


    أضف إلى المفضلة
  5. 5
    Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    المؤلفون: Stéphane Oudard, Benoit Beuselinck, Victoria Neiman, Sabeen Mekan, Frede Donskov, Asim Amin, Philippe Barthélémy, Howard Gurney, David F. McDermott, Christian Kollmannsberger, M. Brent McHenry, Osvaldo Arén Frontera, Ignacio Duran, Camillo Porta, Paul Nathan, Elizabeth R. Plimack, Toni K. Choueiri, Daniel Y.C. Heng, Michael R. Harrison, Raya Leibowitz-Amit, David Pook, Robert J. Motzer, Nizar M. Tannir, Marc-Oliver Grimm, Yoshihiko Tomita, Pamela Salman, Saby George, Sjoukje F. Oosting, Sergio Bracarda, Thomas Powles, CheckMate Investigators, Bruce G. Redman, Viktor Grünwald, Bohuslav Melichar, Bernard Escudier, Hans J. Hammers, Michael A. Carducci, Scott S. Tykodi, Brian I. Rini

    المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS)

    المصدر: Lancet Oncol
    Lancet Oncology, 20(10), 1370-1385. ELSEVIER SCIENCE INC
    Motzer, R J, Rini, B I, McDermott, D F, Arén Frontera, O, Hammers, H J, Carducci, M A, Salman, P, Escudier, B, Beuselinck, B, Amin, A, Porta, C, George, S, Neiman, V, Bracarda, S, Tykodi, S S, Barthélémy, P, Leibowitz-Amit, R, Plimack, E R, Oosting, S F, Redman, B, Melichar, B, Powles, T, Nathan, P, Oudard, S, Pook, D, Choueiri, T K, Donskov, F, Grimm, M O, Gurney, H, Heng, D Y C, Kollmannsberger, C K, Harrison, M R, Tomita, Y, Duran, I, Grünwald, V, McHenry, M B, Mekan, S, Tannir, N M & CheckMate 214 Investigators 2019, ' Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma : extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 20, no. 10, pp. 1370-1385 . https://doi.org/10.1016/S1470-2045Test(19)30413-9

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Population, Medizin, Ipilimumab, Antineoplastic Agents, Article, law.invention, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Sunitinib, Humans, Progression-free survival, Paresthesia, education, Survival rate, Carcinoma, Renal Cell, Fatigue, education.field_of_study, business.industry, Alanine Transaminase, Lipase, Kidney Neoplasms, Progression-Free Survival, Intention to Treat Analysis, Clinical trial, Survival Rate, Nivolumab, Amylases, Hypertension, business, medicine.drug, Follow-Up Studies

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cdd429cbc1f569513fceee7da60507dTest
    https://pubmed.ncbi.nlm.nih.gov/33152309Test


    أضف إلى المفضلة
  6. 6
    Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

    المؤلفون: Cristina Ivanescu, Saby George, Bernard Escudier, Hans J. Hammers, Viktor Grünwald, Sabeen Mekan, Paul Nathan, David Cella, Justin Doan, Brian I. Rini, Marc-Oliver Grimm, Jean Paty, Robert J. Motzer

    المصدر: The Lancet. Oncology. 20(2)

    مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Ipilimumab, Antineoplastic Agents, Article, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, law, Renal cell carcinoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Sunitinib, Humans, Patient Reported Outcome Measures, Carcinoma, Renal Cell, Aged, Neoplasm Staging, business.industry, Middle Aged, medicine.disease, Kidney Neoplasms, Clinical trial, 030104 developmental biology, Nivolumab, Oncology, 030220 oncology & carcinogenesis, Female, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73b54470f3f91619c5ad4335e7ed2a48Test
    https://pubmed.ncbi.nlm.nih.gov/31162102Test


    أضف إلى المفضلة
  7. 7
    An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC)

    المؤلفون: Masayuki Kanai, Sabeen Mekan, Takayuki Yoshino, Yali Liu, Scott Kopetz, Hiroya Taniguchi, Kensei Yamaguchi, Sabine Tejpar, Geetha Pudussery, Arndt Vogel, Zev A. Wainberg, Yang Qiu, Kanwal Pratap Singh Raghav

    المصدر: Journal of Clinical Oncology. 39:TPS157-TPS157

    مصطلحات موضوعية: Cancer Research, Antibody-drug conjugate, Patritumab, Tetrapeptide, Colorectal cancer, medicine.drug_class, business.industry, Phases of clinical research, medicine.disease, Monoclonal antibody, body regions, Oncology, medicine, Cancer research, In patient, skin and connective tissue diseases, business, Linker

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::04a54781b9b7af424ca8f97abeffa88eTest
    https://doi.org/10.1200/jco.2021.39.3_suppl.tps157Test


    أضف إلى المفضلة
  8. 8
    A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors

    المؤلفون: Shiraj Sen, Sabeen Mekan, Melissa Lynne Johnson, Toshihiko Doi, Manish R. Patel, Yasuyuki Okuda, Sarina Anne Piha-Paul, Ben Cheng, Yusuke Myobatake, Gul Serbest, Toshio Shimizu, Johanna C. Bendell

    المصدر: Journal of Clinical Oncology. 38:TPS3646-TPS3646

    مصطلحات موضوعية: Cancer Research, Lung, business.industry, Cancer, A protein, First in human, medicine.disease, Head and neck squamous-cell carcinoma, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Phase i ii, Oncology, Prostate, 030220 oncology & carcinogenesis, Cancer research, medicine, In patient, business, 030215 immunology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::43bdc24cc743288d58517940068b8c59Test
    https://doi.org/10.1200/jco.2020.38.15_suppl.tps3646Test


    أضف إلى المفضلة
  9. 9
    Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    المؤلفون: Sabeen Mekan, Philippe Barthélémy, Marc-Oliver Grimm, Bohuslav Melichar, Allen C. Chen, Robert E. Hawkins, David F. McDermott, Christian Kollmannsberger, Brian I. Rini, M. Brent McHenry, Megan Wind-Rotolo, Sergio Bracarda, Nizar M. Tannir, Carlos H. Barrios, Toni K. Choueiri, Camillo Porta, Osvaldo Arén Frontera, Bernard Escudier, Robert J. Motzer, Yoshihiko Tomita, Justin Doan, Howard Gurney, V. Neiman, Frede Donskov, Alain Ravaud, Pamela Salman, Hans J. Hammers, Daniel Castellano, Thomas Powles, Saby George, Elizabeth R. Plimack, Padmanee Sharma

    المساهمون: Hospital Universitario 12 de Octubre, Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University

    المصدر: CheckMate 214 Investigators 2018, ' Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290 . https://doi.org/10.1056/NEJMoa1712126Test
    Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
    Consejería de Sanidad de la Comunidad de Madrid
    NEW ENGLAND JOURNAL OF MEDICINE

    مصطلحات موضوعية: 0301 basic medicine, Anticuerpos Monoclonales, Male, Indoles, MULTICENTER, Supervivencia sin Enfermedad, urologic and male genital diseases, THERAPY, 0302 clinical medicine, Antineoplastic Agents, Immunological, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Sunitinib, Tasa de Supervivencia, Ipilimumab/administration & dosage, Masculino, Aged, 80 and over, Persona de Mediana Edad, KIDNEY CANCER, Adulto, Antibodies, Monoclonal, PHASE-III TRIAL, General Medicine, Indoles/administration & dosage, Middle Aged, OPEN-LABEL, Kidney Neoplasms, Humanos, Axitinib, Survival Rate, Kidney Neoplasms/drug therapy, Nivolumab, 030220 oncology & carcinogenesis, Antineoplásicos Inmunológicos, medicine.drug, Protocolos de Quimioterapia Combinada Antineoplásica, Adult, Risk, medicine.medical_specialty, Análisis de Supervivencia, Anciano, Urology, Ipilimumab, Riesgo, Antibodies, Monoclonal/administration & dosage, Disease-Free Survival, PAZOPANIB, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Syöpätaudit - Cancers, medicine, Carcinoma, Humans, Pyrroles, SYMPTOM INDEX, Carcinoma de Células Renales, Survival rate, Carcinoma, Renal Cell, Survival analysis, Aged, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Pyrroles/administration & dosage, UNTREATED MELANOMA, medicine.disease, Pirroles, Survival Analysis, Anciano de 80 o más Años, 1ST-LINE TREATMENT, 030104 developmental biology, Carcinoma, Renal Cell/drug therapy, Quality of Life, Calidad de Vida, INTERFERON-ALPHA, business, Neoplasias Renales

    وصف الملف: application/pdf; fulltext

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be20ad4dc575b4b2b082a5f7053e6c4Test
    https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinomaTest(9d613da7-a490-4e1e-940a-79cc1309b512).html


    أضف إلى المفضلة
  10. 10
    Caractérisation de la réponse au traitement par nivolumab plus ipilimumab (N+I) ou sunitinib (S) chez des patients (pts) atteints d’un carcinome à cellules rénales avancé (CCRa) non préalablement traité : CheckMate 214

    المؤلفون: Bernard Escudier, Thomas Powles, Nizar M. Tannir, Viktor Grünwald, Howard Gurney, C. Porta, T.K. Choueri, Hans J. Hammers, M.-O. Grimm, D.Y.C. Heng, Sabeen Mekan, Saby George, M.B. McHenry, Brian I. Rini, Scott S. Tykodi, Robert J. Motzer, David F. McDermott, Christian Kollmannsberger, Michael R. Harrison

    المصدر: Progrès en Urologie. 28:624-625

    مصطلحات موضوعية: Gynecology, medicine.medical_specialty, business.industry, Urology, Medicine, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::6a01ca98ae06ce37aa029e4eccf2070bTest
    https://doi.org/10.1016/j.purol.2018.07.033Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث